Immune System Diseases

905 trials 381 recruiting

Filter these 905 trials by phase, country and sponsor.

Open in Search →

A Safety and Tolerability Study of VRDN-001 in Persons with Thyroid Eye Disease (TED) Ended

2023-507563-19-00 Thyroid eye disease 5 2024-11-05
Long-Term Extension Study (AtDvance) to Evaluate the Safety and Efficacy of GSK1070806 in Participants with Moderate to Severe Atopic Dermat… Ended

2023-508474-29-00 Dermatitis, Atopic 4 2024-10-30
A prospective, randomized, double-blind placebo-controlled multicentre trial with mannan-conjugated birch pollen allergoids administered sub… Ended

2024-515717-17-00 birch pollen-induced allergic rhinitis birch pollen-ind 5 2024-10-28
SCLERITA - Safety and efficacy of itacitinib in adults with systemic sclerosis: a phase II, randomized, controlled trial Ended

2024-513648-27-00 Patients with newly or active diffuse Systemic sclerosi 4 2024-10-25
A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) wi… Ended

2023-506664-14-00 Rheumatoid Arthritis 5 2024-10-24
Lepidoglyphus destructor extract. Determination of in vivo allergenic potency in histamine equivalent prick testing units (HEP). Ended

2023-509541-13-00 Allergy to Lepidoglyphus destructor 4 2024-10-23
Safety Assessment of 10-Day Daily Bucco-Oral Administration of Transfer Factor in Healthy Adult Human Subjects Ended

2024-511448-17-02 healthy subjects 1 2024-10-16
A Phase 1, Open-label, Randomized, Crossover Study to Assess the Effect of Different Types of Co-administered Oral Liquids on the Relative O… Ended

2024-515230-32-00 Inflammatory Conditions 3 2024-10-09
An open label, balanced, randomized, two-treatment, four period, two-sequence, multiple-dose (steady-state), fully-replicate crossover bioeq… Ended

2024-512770-10-00 Rheumatoid arthritis, ulcerative colitis, atopic dermat 2 2024-10-07
A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe … Ended

2024-511360-87-00 hidradenitis suppurativa (HS) 5 2024-10-02
A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe … Ended

2024-511363-28-00 hidradenitis suppurativa (HS) 5 2024-09-24
A study to evaluate the safety and tolerability of JNJ-70035108 and to evaluate how long JNJ-70035108 stays in and acts on the body (pharmac… Ended

2024-514067-25-00 Inflammatory Conditions 1 2024-09-23
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Upadaci… Ended

2024-512771-12-00 Axial spondyloarthritis 2 2024-09-17
Multicenter, Prospective, Open-label, Randomized, Crossover Study to Evaluate Pharmacokinetics (PK), Safety, and Tolerability of TAK-881 in … Ended

2022-502095-23-01 Primary Immunodeficiency Diseases 10 2024-09-10
PIMOC - Personalized targeted therapies in inflammatory complex multi organ disease Ended

2024-513647-86-00 Patients displaying a non-classified, severe and resist 4 2024-09-09
A TQT Study to Investigate the Effect of Enpatoran on Cardiac Repolarization in Healthy Participants Ended

2024-512841-17-00 Healthy 3 2024-09-04
Effect of Renal Impairment on Enpatoran Pharmacokinetics Ended

2024-513393-22-00 Healthy volunteers and patients with renal impairment; 3 2024-09-04
Phase II-III study to assess the efficacy and safety of subcutaneous cluster-immunotherapy in patients suffering from Olea europaea pollen a… Ended

2024-511383-88-00 Moderate-to-severe allergic rhinitis / rhinoconjunctivi 10 2024-09-01
A study to learn if a Zilucoplan auto-injector is safe and works in adults with myasthenia gravis Ended

2023-508287-30-00 Generalized Myasthenia Gravis 5 2024-08-29
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutane… Ended

2023-504942-75-01 Moderate to Severe Allergic Rhinitis/Rhinoconjunctiviti 5 2024-08-22
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Upadaci… Ended

2024-512773-27-00 Rheumatoid arthritis, ulcerative colitis, atopic dermat 2 2024-08-19
A Phase 3, Placebo-controlled, Cross-over Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Attacks in Adolescents and Adu… Ended

2023-507268-37-00 Hereditary Angioedema 5 2024-07-29
A study to investigate immune challenge induced skin reactions with SAR445399, canakinumab and spesolimab compared with placebo, in healthy … Ended

2024-511241-19-00 Immuun system diseases 3 2024-07-19
Open-Label Study of Imdusiran (AB-729) in Combination with Intermittent Dosing of Durvalumab in Subjects with Chronic HBV Infection Ended

2023-509573-23-00 Chronic HBV Infection 4 2024-07-16